Tag
An exploratory ARCADIA analysis suggests that patients with cryptogenic stroke and atrial cardiopathy without severe hypertension-related features may derive greater benefit from apixaban than aspirin, whereas those with high-risk hypertens
In ARTESiA patients with device-detected subclinical AF, apixaban reduced thromboembolism but increased major bleeding—primarily noncritical gastrointestinal events—while intracranial and fatal bleeding rates were similar to aspirin.
A secondary analysis of the ARCADIA trial reveals that apixaban significantly reduces recurrent ischemic stroke risk compared to aspirin in patients with left ventricular systolic dysfunction post-cryptogenic stroke.
Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti
A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.
